Posters

      Cigarette smoke-induced perturbations of molecular pathways in human organotypic cultures of buccal and gingival mucosa

      Cabanski, M.; Mathis, C.; Iskandar, A.; Kostadinova, R.; Frentzel, S.; Kuehn, D.; Majeed, S.; Geertz, M.; Talamo, F.; Guedj, E.; Xiang, Y.; Martin, F.; Schlage, W. K.; Hayes, A. W.; Peitsch, M. C.; Hoeng, J.

      Conference date
      Mar 23, 2014
      Conference name
      Society of Toxicology (SOT) 2014
      Link to more information
      Topic
      Summary

      Smoker’s oral mucosa is subject to cigarette smoke (CS)-induced cytological, genomic, and transcriptional changes that could potentially lead to the development of mouth disease. To characterize cs effects, we used two human organotypic in vitro models of the buccal and gingival epithelia (MatTek®). Both in vitro models were exposed at the air-liquid interface to fresh, diluted CS (one reference cigarette 3R4F at a time, with Health Canada smoking regimen and nicotine doses of 0.279 mg/l or 0.557 mg/l) on 4 occasions with 1h intervals between exposures where the tissues were kept in the incubator under appropriate culture conditions. Systems biology endpoints (gene and miRNA expression) were determined at time 0 following the 4th exposure and 4h, 24h, 48h after exposure to investigate time- and dose-dependent CS effect on both tissues. Other endpoints (e.g. cytotoxicity, pro-inflammatory marker release, cytochrome P450 (CYP) activity, histology) were also measured for some time points. The release of pro-inflammatory markers such as vegf and mmp-1 was up-regulated in both cs-exposed buccal and gingival tissues 24h after exposure. However, only gingival tissues showed a significant up-regulation of CYP1A1/CYP1B1 activity 48h after exposure. By using computational approaches and by capturing systems biology endpoints, various perturbations of biological processes (e.g. inflammation, proliferation, cellular stress,) triggered by repeated CS exposure were observed in both buccal and gingival in vitro models. We describe here for the first time the impact of CS exposure on human buccal and gingival organotypic models using various approaches combining systems biology, biological network models, computational methods and standard endpoints. 

      Related Publications

      Indoor Air Chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

      Aerosol Chemistry

      Indoor air chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

      Aerosol Chemistry

      Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

      Aerosol Chemistry

      Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

      Aerosol Chemistry

      Air quality assessment during indoor use of the Tobacco Heating System 2.2

      Aerosol Chemistry

      Air quality assessment during indoor use of the Tobacco Heating System THS 2.2

      Aerosol Chemistry

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.